Anteris Technologies Global Corp (AVR) Stock AnalysisAVRAnteris Technologies Global Corp

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system. It operates in the Healthcare sector.

Anteris Technologies is currently trading at $6.77, significantly below the analyst price target of $18, indicating potential upside. However, the RSI is at a low 23.84, suggesting the stock is oversold and may not be the best buy at this moment. The company has a gross margin of 76.91%, which is strong, but it also reported a net income loss of $28.79 million in Q2 2026, highlighting ongoing financial challenges. The main risk is the recent 5-day change of -12.19%, indicating downward momentum.